| Bestanddeel | Pre | 0-3 | 4-6 | 7-9 | Peri | Borstvoeding |
|---|---|---|---|---|---|---|
| Antitumorale middelen • Targeted therapie • Proteïnekinase-inhibitoren • EGFR-inhibitoren Up | ||||||
| ERLOTINIB(oraal) | check | check | check | check | check | neen |
| LAPATINIB(oraal) | check | neen | neen | neen | neen | neen |
| GEFITINIB(oraal) | check | neen | check | check | check | neen |
| AFATINIB(oraal) | neen | check | check | check | check | check |
| OSIMERTINIB(oraal) | neen | neen | neen | neen | neen | neen |
| Bestanddeel | Pre | 0-3 | 4-6 | 7-9 | Peri | Borstvoeding |
|---|---|---|---|---|---|---|
| Antitumorale middelen • Targeted therapie • Proteïnekinase-inhibitoren • EGFR-inhibitoren Up | ||||||
| ERLOTINIB(oraal) | check | check | check | check | check | neen |
| LAPATINIB(oraal) | check | neen | neen | neen | neen | neen |
| GEFITINIB(oraal) | check | neen | check | check | check | neen |
| AFATINIB(oraal) | neen | check | check | check | check | check |
| OSIMERTINIB(oraal) | neen | neen | neen | neen | neen | neen |